Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

What is CIDP?

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes inflammation of your body’s nerves. Though your immune system generally keeps you healthy by fighting off germs, with CIDP, your immune system does not recognize parts of your nerves and attacks them.

Specifically, the immune system mistakenly attacks your nerves’ protective myelin. When the myelin is damaged or removed, messages transmitted to and from the brain are disrupted and may never make it to their final destination.

Over time, this may cause gradual weakness, numbness and a loss of feeling in your arms and legs. If left untreated, CIDP can cause permanent damage to the nerves.

FREE WEBINAR WEDNESDAYS - These programs feature a presentation from a trained nurse who treats CIDP and stories from a CIDP patient. Take part in our live webinar series where you can ask questions and join in the discussion from the convenience of your home. Register Here on Hizentra.com.

The symptoms of CIDP include numbness, weakness and tingling of the arms and legs.

What is myelin?

Nerves are responsible for sending messages to and from the brain, like when you want your hand to grasp an object or when your hand tells your brain the stove is hot. Healthy nerves are wrapped in a sheath called myelin, much like electric wires wrapped in rubber insulation. The insulation allows electric impulses to travel efficiently along.

Living with CIDP

Elizabeth Thirtyacre is living with chronic inflammatory demyelinating polyneuropathy, also known as CIDP. The rare neurological disorder can cause muscle and nerve damage and lead to pain and weakness among other symptoms. She advises patients like her to listen to their body.

Watch Elizabeth's tips

Vita: Related Stories

Coming Soon – CSL Behring Academy: Immunology

The March 15-17 event offers a hybrid learning opportunity for doctors and other health care providers who want a deep dive i…

20 Jan 2023

Photo of Arthur, a CIDP patient, sitting outside in a ball cap holding a slice of pizza.

Watch: Arthur's CIDP Story

Arthur is stepping forward for those also living with chronic inflammatory demyelinating polyneuropathy (CIDP).

30 Nov 2022

Polly, a young CIDP patient, recovers in the hospital.

Returning Life to Polly's Limbs

In USA TODAY: When a 12-year-old experienced numbing inflammation, then paralysis, a plasma-based medicine was the answer.

14 Oct 2021

Resources for you

RESOURCE	DESCRIPTION
Hizentra CIDP Facebook	Provides CIDP patients and their families with information on Hizentra, patient stories and support programs.	Visit Facebook
GBS/CIDP Foundation International	Global non-profit organization supporting individuals and families affected by GBS, CIDP, or related syndromes such as MMN.	View Website
National Organization of Rare Disorders (NORD)	CIDP overview from a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them.	View Website

Treatments Available

Availability of treatments may vary from country to country. Please be sure to visit your local CSLBehring.com site for further information.

Privigen® \| Immune Globulin Intravenous (Human) 10% Liquid
US Prescribing Information
US Important Safety Information (Selected)
WARNINGS: Thrombosis (blood clotting) can occur with immune globulin products, including Privigen. Risk factors may include advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (thick blood), use of estrogens, installed vascular catheters, and cardiovascular risk factors. In predisposed patients, kidney malfunction and acute kidney failure, potentially fatal, can occur with the administration of human immune globulin intravenous (IGIV) products. Kidney problems occur more commonly in patients receiving IGIV products that contain sucrose. Privigen does not contain sucrose. If you are at high risk of thrombosis or kidney problems, your doctor will prescribe and administer Privigen at the minimum dose and infusion rate practicable, and will monitor you for signs and symptoms of thrombosis and viscosity, as well as kidney function. Always drink sufficient fluids before administration. See your doctor for a full explanation, and the full prescribing information for complete boxed warning. In clinical trials of Privigen, headache was the most common side effect. Other common side effects that can be seen with treatment include fatigue, nausea, fever, and high blood pressure. These are not the only side effects possible; see the full prescribing information for a complete list of adverse reactions possible with treatment for each condition. Alert your physician to any side effect that bothers you or does not go away.
Full US Important Safety Information

Hizentra® \| Immune Globulin Subcutaneous (Human) 20% Liquid
US Prescribing Information
US Important Safety Information (Selected)
WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors include: advanced age, prolonged immobilization, a history of blood clotting or blood thickness, use of estrogens, installed vascular catheters, and cardiovascular risk factors. If you are at high risk of blood clots, your doctor will prescribe the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra. See your doctor for a full explanation, and the full prescribing information for complete boxed warning. The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.
Full US Important Safety Information

Participate in Clinical Trials

Discover what is involved in participating in one of our clinical trials and how you can enroll.

Learn More